Bausch + Lomb is a prominent global eye health business dedicated to enhancing and protecting vision for people at all life stages. With a comprehensive portfolio exceeding 400 products, the company offers a wide range of solutions, including contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, and surgical devices. It operates in three primary segments: vision care, surgical, and ophthalmic pharmaceuticals. The vision care segment includes contact lenses, where the company holds a notable market share, as well as ocular health products such as Biotrue and Lumify. The surgical segment provides essential tools and technologies for cataract and vitreoretinal surgeries, including intraocular lenses and surgical instruments. Additionally, the ophthalmic pharmaceuticals segment features a variety of treatments for eye conditions, including products like Xipere, Vyzulta, and Lotemax. Bausch + Lomb's commitment to eye health underscores its mission to serve millions globally.
Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.
Whitecap Biosciences
Acquisition in 2025
5, Whitecap Biosciences is a pharmaceutical firm that specializes in developing innovative treatments for ocular conditions, such as glaucoma and geographic atrophy, two of the main causes of blindness in ophthalmology.
Xiidra
Acquisition in 2023
Xiidra is a pharmaceutical company that specializes in developing a prescription eye drop solution aimed at treating the signs and symptoms of dry eye disease (DED). The product is a non-steroidal eye drop that specifically addresses the inflammation associated with DED, providing relief to individuals suffering from this condition. By focusing on both the symptoms and underlying causes of dry eye disease, Xiidra offers an effective treatment option for patients seeking to manage their discomfort.
Libvatrep
Acquisition in 2023
Libvatrep is a medication being researched for the treatment of chronic ocular surface pain.
AcuFocus
Acquisition in 2023
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.
AcuFocus
Venture Round in 2014
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.
Technolas Perfect Vision
Acquisition in 2012
Technolas Perfect Vision GmbH is a prominent company in the field of ophthalmology, specializing in laser technologies for diagnostic and therapeutic services. Established as a joint venture between Bausch + Lomb and 20/10 PERFECT VISION AG, the company offers a comprehensive range of solutions in both femtosecond and excimer laser applications. Its current innovations are centered on advancing laser cataract surgery and addressing presbyopia through its SUPRACOR™ laser treatment. Technolas Perfect Vision serves refractive and cataract surgeons, enhancing surgical outcomes with its cutting-edge technologies in vitreoretinal surgery and presbyopic treatment.
Ista Pharmaceuticals
Acquisition in 2012
ISTA Pharmaceuticals is a commercial-stage pharmaceutical company based in Irvine, California, focused on developing and marketing treatments for various eye diseases and conditions. Founded in 1992, the company specializes in remedies for ocular inflammation, glaucoma, dry eye, and allergies. Its marketed products include BROMDAY, an ophthalmic solution for postoperative inflammation and pain, BEPREVE for allergic conjunctivitis, ISTALOL for glaucoma, and VITRASE, used as a spreading agent in ocular treatments. ISTA is also engaged in developing several products, including over-the-counter artificial tears, PROLENSA for postoperative pain relief, and various nasal sprays for allergic rhinitis. The company sells its products to a broad range of customers, including drug wholesalers, retail pharmacies, hospitals, and managed healthcare providers. As of June 2012, ISTA Pharmaceuticals operates as a subsidiary of Bausch & Lomb Incorporated.
AcuFocus
Venture Round in 2011
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.
AcuFocus
Series D in 2007
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.
AcuFocus
Private Equity Round in 2007
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.